Physician Guide
Non-Opioid Intrathecal Therapy Pain Medication
IMPORTANT SAFETY INFORMATION
WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS
PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.

PRIALT Mechanism of Action

Page 1 of 2

Dr. Jason E Pope* discusses the proposed mechanism of action (MOA) of PRIALT. Dr. Pope is the President of Summit Pain Alliance in Santa Rosa, California, and is Scientific Program Chair and on the Board of Directors of the North American Neuromodulation Society (NANS).
 

 

Key Takeaway Points

PRIALT is the only non-opioid option approved by the FDA for IT analgesia in adults with severe chronic pain. PRIALT works differently – results in animal studies suggest that PRIALT blocks N-type calcium channels at the dorsal horn of the spinal cord to inhibit pain transmission. In animal models, intrathecal ziconotide potentiated opioid-induced reduction in gastrointestinal (GI) motility, but did not potentiate morphine-induced respiratory depression.

PRIALT does not bind to opioid receptors and its pharmacologic effects are not blocked by opioid antagonists.

*Jason E. Pope, MD is a paid consultant for Jazz Pharmaceuticals.

©2018 Jazz Pharmaceuticals plc or its subsidiaries.
PRI-0186(1)
Last updated on: May 25, 2018
SHOW MAIN MENU
SHOW SUB MENU